Evidence map›Paper›PMID 42741554›Full record

ArticleClinical kidney journal2026

Long-term kidney and patient outcomes in pure versus mixed lupus membranous nephritis.

Martina Uzzo, Marisol Bracalenti, Marta Calatroni, Barbara Trezzi, Emanuele Conte, Laura Locatelli, Mariele Gatto, Roberto Depascale, Giovanni Maria Rossi, Vincenzo Limperio and 3 more

Abstract read
In one paragraph

Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Martina UzzoNephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID https://orcid.org/0009-0004-6046-5501
Marisol BracalentiRheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
Marta CalatroniNephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Barbara TrezziNephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Emanuele ConteNephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Laura LocatelliNephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Mariele GattoAcademic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Turin, Italy.ORCID https://orcid.org/0000-0003-4012-1248
Roberto DepascaleRheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
Giovanni Maria RossiNephrology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Vincenzo LimperioDepartment of Medicine and Surgery, Pathology, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy.
Renato Alberto SinicoNephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Andrea DoriaRheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0003-0548-4983
Gabriella Luisa MoroniNephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Pure membranous lupus nephritis [pMLN, Class V International Society of Nephrology/Renal Pathology Society (ISN/RPS)] is traditionally considered less aggressive than mixed forms of MLN (mMLN, Classes III/IV ± V ISN/RPS). Only two trials have compared the outcome of these two forms of MLN, with inconclusive results. In this retrospective multicentre study, we assessed and compared the short and long-term outcomes of pMLN versus mMLN. Methods: Patients diagnosed with pMLN or mMLN on their first kidney biopsy were included. The main outcomes were complete renal response after 1 year, sustained complete response, relapse rates, chronic kidney disease (CKD)-free survival, and the composite outcome of kidney failure (KF)/death-free survival. Results: Of the 195 patients included, 96 (49.2%) pMLN had milder immunological features of active LN at baseline compared to 99 (50.8%) with mMLN. At kidney biopsy, the National Institute of Health activity and chronicity indices were lower in patients with pMLN ( Conclusion: This study challenges the long-standing view of pMLN as a generally benign condition, suggesting that less intensive treatment of pure MLN may have contributed to less favourable hard outcomes in the long-term.

Indexed as

classificationhistologykidney biopsylupus nephritis

Identifiers

PMID42741554
PMCPMC13572870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.